These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1464 related items for PubMed ID: 27391315

  • 1. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
    Inciarte-Mundo J, Ramirez J, Hernández MV, Ruiz-Esquide V, Cuervo A, Cabrera-Villalba SR, Pascal M, Yagüe J, Cañete JD, Sanmarti R.
    Arthritis Res Ther; 2016 Jul 08; 18(1):160. PubMed ID: 27391315
    [Abstract] [Full Text] [Related]

  • 2. Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors.
    Inciarte-Mundo J, Victoria Hernández M, Ruiz-Esquide V, Raquel Cabrera-Villalba S, Ramirez J, Cuervo A, Pascal M, Yagüe J, Cañete JD, Sanmarti R.
    Arthritis Care Res (Hoboken); 2016 Jul 08; 68(7):899-906. PubMed ID: 26841119
    [Abstract] [Full Text] [Related]

  • 3. Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study.
    Inciarte-Mundo J, Ramirez J, Hernández MV, Ruiz-Esquide V, Cuervo A, Cabrera-Villalba SR, Pascal M, Yagüe J, Cañete JD, Sanmarti R.
    Arthritis Res Ther; 2018 Dec 13; 20(1):275. PubMed ID: 30545393
    [Abstract] [Full Text] [Related]

  • 4. Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?
    Alivernini S, Tolusso B, Petricca L, Bui L, Di Sante G, Peluso G, Benvenuto R, Fedele AL, Federico F, Ferraccioli G, Gremese E.
    Ann Rheum Dis; 2017 Jul 13; 76(7):1228-1236. PubMed ID: 28119289
    [Abstract] [Full Text] [Related]

  • 5. Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis.
    Hurnakova J, Zavada J, Hanova P, Hulejova H, Klein M, Mann H, Sleglova O, Olejarova M, Forejtova S, Ruzickova O, Komarc M, Vencovsky J, Pavelka K, Senolt L.
    Arthritis Res Ther; 2015 Sep 15; 17(1):252. PubMed ID: 26373925
    [Abstract] [Full Text] [Related]

  • 6. Serum calprotectin as a marker of ultrasound-detected synovitis in early psoriatic and rheumatoid arthritis: results from a cross-sectional retrospective study.
    Sakellariou G, Lombardi G, Vitolo B, Gomarasca M, Faraldi M, Caporali R, Banfi G, Montecucco C.
    Clin Exp Rheumatol; 2019 Sep 15; 37(3):429-436. PubMed ID: 30299248
    [Abstract] [Full Text] [Related]

  • 7. Power Doppler ultrasound monitoring of response to anti-tumour necrosis factor alpha treatment in patients with rheumatoid arthritis.
    Iagnocco A, Finucci A, Ceccarelli F, Perricone C, Iorgoveanu V, Valesini G.
    Rheumatology (Oxford); 2015 Oct 15; 54(10):1890-6. PubMed ID: 26070937
    [Abstract] [Full Text] [Related]

  • 8. Calprotectin (S100A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis.
    Nordal HH, Brokstad KA, Solheim M, Halse AK, Kvien TK, Hammer HB.
    Arthritis Res Ther; 2017 Jan 12; 19(1):3. PubMed ID: 28081709
    [Abstract] [Full Text] [Related]

  • 9. Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants.
    Inciarte-Mundo J, Ruiz-Esquide V, Hernández MV, Cañete JD, Cabrera-Villalba SR, Ramirez J, Yagüe J, Sanmarti R.
    Rheumatology (Oxford); 2015 Dec 12; 54(12):2239-43. PubMed ID: 26242859
    [Abstract] [Full Text] [Related]

  • 10. Clinical and sonographic biomarkers of structural damage progression in RA patients in clinical remission: A prospective study with 12 months follow-up.
    Ramírez J, Narváez JA, Ruiz-Esquide V, Hernández-Gañán J, Cuervo A, Inciarte-Mundo J, Hernández MV, Sampayo-Cordero M, Pablos JL, Sanmartí R, Cañete JD.
    Semin Arthritis Rheum; 2017 Dec 12; 47(3):303-309. PubMed ID: 28549731
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Utility of Power Doppler Ultrasound-detected Synovitis for the Prediction of Short-term Flare in Psoriatic Patients with Arthritis in Clinical Remission.
    Ruta S, Marin J, Acosta Felquer ML, Ferreyra-Garrot L, Rosa J, García-Monaco R, Soriano ER.
    J Rheumatol; 2017 Jul 12; 44(7):1018-1023. PubMed ID: 28461647
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission.
    Hurnakova J, Hulejova H, Zavada J, Komarc M, Hanova P, Klein M, Mann H, Sleglova O, Olejarova M, Forejtova S, Ruzickova O, Vencovsky J, Pavelka K, Senolt L.
    PLoS One; 2016 Jul 12; 11(11):e0165498. PubMed ID: 27832086
    [Abstract] [Full Text] [Related]

  • 18. Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis.
    Chandran V, Shen H, Pollock RA, Pellett FJ, Carty A, Cook RJ, Gladman DD.
    J Rheumatol; 2013 Jun 12; 40(6):866-71. PubMed ID: 23637322
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 74.